多靶点抗肿瘤新药crizotinib的研究进展  

Crizotinib:a novel multi-targeted anti-tumor drug

作　　者：周文菁[1,2] 刘韬[1] 贾守薇[1] 周望[1] 吴琳[2] 黄红兵[1] 

机构地区：[1]华南肿瘤学国家重点实验室、中山大学附属肿瘤医院,广东广州510060 [2]广州市第一人民医院,广东广州510180

出　　处：《中国新药与临床杂志》2013年第8期595-598,共4页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：Crizotinib是一种口服多激酶抑制药，针对c—Met和EML4-ALK融合基因为靶点，抑制肿瘤细胞增殖。I期临床试验的推荐剂量为250mg，每日二次。EML4-ALK融合基因的发生率约为4％～7％．I／Ⅱ期临床试验表明ALK阳性的患者在多程治疗后接受crizotinib治疗1年生存率可达77％，2年生存率为64％，且安全性良好。目前，crizotinibm期临床试验正在进行中，FDA已批准其用于ALK阳性的局部晚期和转移的非小细胞肺癌治疗。Crizotinib is a novel oral multi-targeted tyrosine kinase inhibitor that inhibits c-Met and EML4- ALK fusion gene. Phase I clinical recommended the drug dose of 250 rag, twice daily. EML4-ALK is a fusion oncogene found in approximately 4% - 7% of patients with non- small- cell lung cancer. I/II clinical trial showed that the one year survival rate of patients who harbor ALK transIocation treated by crizotinib after several lines was 77%, and the two years survival rate was 64%. Currently, the crizotinib m clinical trial is ongoing, and the FDA has proved crizotinib for the treatment of patients with advanced non-small-cell lung cancer whose tumors are ALK-positive.

关 键 词：CRIZOTINIB EML4-ALK基因 癌 非小细胞肺 酪氨酸激酶抑制剂 抗肿瘤药 

分 类 号：R979.1[医药卫生—药品]